http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 08:23:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Ribo+reports+Phase+2a+data+on+vortosiran+for+coronary+artery+disease/26798681.html <p>Suzhou Ribo Life Science Co. (HKEx: 06938) and its subsidiary Ribocure Pharmaceuticals AB announced Phase 2a trial results for vortosiran (RBD4059), an siRNA therapy targeting coagulation Factor XI, in patients with chronic coronary artery disease.</p> <p>The randomized, double-blind, placebo-controlled study found that patients in the high-dose group receiving a 400mg maintenance dose achieved a mean maximum reduction in FXI activity of 92%, which the company said was sustained for several months following dosing. The results were presented at the China Pharmaceutical Innovation Conference in Shanghai on July 22, 2026.</p> <p>The trial enrolled patients with chronic coronary artery disease and a history of http://www.streetinsider.com/FDA/Ribo+reports+Phase+2a+data+on+vortosiran+for+coronary+artery+disease/26798681.html Wed, 22 Jul 2026 08:23:37 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/FDA/Ribo+reports+Phase+2a+data+on+vortosiran+for+coronary+artery+disease/26798681.html <p>Suzhou Ribo Life Science Co. (HKEx: 06938) and its subsidiary Ribocure Pharmaceuticals AB announced Phase 2a trial results for vortosiran (RBD4059), an siRNA therapy targeting coagulation Factor XI, in patients with chronic coronary artery disease.</p> <p>The randomized, double-blind, placebo-controlled study found that patients in the high-dose group receiving a 400mg maintenance dose achieved a mean maximum reduction in FXI activity of 92%, which the company said was sustained for several months following dosing. The results were presented at the China Pharmaceutical Innovation Conference in Shanghai on July 22, 2026.</p> <p>The trial enrolled patients with chronic coronary artery disease and a history of http://www.streetinsider.com/FDA/Ribo+reports+Phase+2a+data+on+vortosiran+for+coronary+artery+disease/26798681.html Wed, 22 Jul 2026 08:23:37 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/FDA/Ribo+reports+Phase+2a+data+on+vortosiran+for+coronary+artery+disease/26798681.html <p>Suzhou Ribo Life Science Co. (HKEx: 06938) and its subsidiary Ribocure Pharmaceuticals AB announced Phase 2a trial results for vortosiran (RBD4059), an siRNA therapy targeting coagulation Factor XI, in patients with chronic coronary artery disease.</p> <p>The randomized, double-blind, placebo-controlled study found that patients in the high-dose group receiving a 400mg maintenance dose achieved a mean maximum reduction in FXI activity of 92%, which the company said was sustained for several months following dosing. The results were presented at the China Pharmaceutical Innovation Conference in Shanghai on July 22, 2026.</p> <p>The trial enrolled patients with chronic coronary artery disease and a history of http://www.streetinsider.com/FDA/Ribo+reports+Phase+2a+data+on+vortosiran+for+coronary+artery+disease/26798681.html Wed, 22 Jul 2026 08:23:37 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and MOLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location>, the positive results from a Phase 2a study in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html Wed, 22 Jul 2026 08:22:00 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and MOLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location>, the positive results from a Phase 2a study in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html Wed, 22 Jul 2026 08:22:00 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and MOLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location>, the positive results from a Phase 2a study in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html Wed, 22 Jul 2026 08:22:00 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and MOLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location>, the positive results from a Phase 2a study in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html Wed, 22 Jul 2026 08:22:00 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and MOLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location>, the positive results from a Phase 2a study in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html Wed, 22 Jul 2026 08:22:00 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and MOLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location>, the positive results from a Phase 2a study in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+Discloses+Positive+Data+from+Vortosiran+Phase+2a+Trial+-+World%27s+First+Clinical+Data+on+siRNA-Mediated+FXI+Inhibition+Following+Multiple+Dosing+in+Patients+with+Coronary+Artery+Disease/26798680.html Wed, 22 Jul 2026 08:22:00 -0400 6938 A.50216913 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> (06938.HK), and its subsidiary <span value="ACORN:5021691372" idsrc="xmltag.org" >Ribocure Pharmaceuticals AB</span> (collectively referred to as "Ribo"), in collaboration with <span value="NASDAQ-SMALL:MDGL" idsrc="xmltag.org" >Madrigal Pharmaceuticals, Inc.</span> (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ribo+and+Madrigal+Reach+First+Major+Milestone+in+Advancing+Novel+siRNA+Therapies+for+MASH/26722776.html Wed, 01 Jul 2026 21:19:00 -0400 6938 A.50216913 MDGL O.00186624 O.54275273 http://www.streetinsider.com/Press+Releases/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>May 6, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> and <span>Ribocure Pharmaceuticals AB</span> ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html Wed, 06 May 2026 07:21:00 -0400 6938 A.31197700 O.00831659 http://www.streetinsider.com/Press+Releases/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>May 6, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> and <span>Ribocure Pharmaceuticals AB</span> ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html Wed, 06 May 2026 07:21:00 -0400 6938 A.31197700 O.00831659 http://www.streetinsider.com/Press+Releases/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>May 6, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> and <span>Ribocure Pharmaceuticals AB</span> ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html Wed, 06 May 2026 07:21:00 -0400 6938 A.31197700 O.00831659 http://www.streetinsider.com/PRNewswire/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>May 6, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> and <span>Ribocure Pharmaceuticals AB</span> ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html Wed, 06 May 2026 07:21:00 -0400 6938 A.31197700 O.00831659 http://www.streetinsider.com/PRNewswire/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>May 6, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> and <span>Ribocure Pharmaceuticals AB</span> ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html Wed, 06 May 2026 07:21:00 -0400 6938 A.31197700 O.00831659 http://www.streetinsider.com/PRNewswire/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location> and MÖLNDAL, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>May 6, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:6938" idsrc="xmltag.org" >Suzhou Ribo Life Science Co., Ltd.</span> and <span>Ribocure Pharmaceuticals AB</span> ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ribo+and+Boehringer+Ingelheim+further+progress+their+siRNA+program+for+metabolic+dysfunction-associated+steatohepatitis+%28MASH%29/26439065.html Wed, 06 May 2026 07:21:00 -0400 6938 A.31197700 O.00831659